G. Hemmings

发表

Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial

M. D. James, R. Butler, P. Quirke, 2015, Journal of Clinical Pathology.

FOCUS4 biomarker laboratories: from the benefits to the practical and logistical issues faced during 6 years of centralised testing

R. Butler, P. Quirke, B. Jasani, 2022, Journal of Clinical Pathology.

Combined epiregulin (EREG) and amphiregulin (AREG) expression levels as a biomarker of prognosis and panitumumab benefit in RAS-wt advanced colorectal cancer (aCRC).

J. Barrett, P. Quirke, S. Tejpar, 2014 .

GBMdeconvoluteR accurately infers proportions of neoplastic and immune cell populations from bulk glioblastoma transcriptomics data

R. Verhaak, David McDonald, A. Filby, 2022, bioRxiv.

Intra-tumoral Heterogeneity of KRAS and BRAF Mutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing

P. Quirke, S. Richman, C. Daly, 2011, Analytical cellular pathology.

HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials

J. Barrett, D. Kerr, R. Gray, 2016, The Journal of pathology.

Clinical and molecular characteristics and treatment outcomes of advanced right-colon, left-colon and rectal cancers: data from 1180 patients in a phase III trial of panitumumab with an extended biomarker panel.

J. Barrett, P. Quirke, S. Tejpar, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations

P. Quirke, J. Worlding, S. Beare, 2017, British Journal of Cancer.

The role of Light-Sheet microscopy in understanding early (pT1/2) colorectal cancer development

G. Hemmings, Hayley L. Slaney, G. Mappa, 2019 .

Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer.

J. Barrett, P. Quirke, S. Tejpar, 2016, JAMA oncology.

KRAS and BRAF mutations in Nigerian colorectal cancers.

H. Grabsch, P. Quirke, F. Abdulkareem, 2012, West African journal of medicine.

GEMS–RCPSG: ‘Is Academic Medicine for Me?’ National Conference 2011, 19 November 2011

H. Branigan, D. Webb, H. Grabsch, 2012 .

M. D. James, R. Butler, B. Jasani, 2023 .

KRAS and BRAF Mutational Status can be Accurately Determined on Diagnostic Tissue Biopsies: An Analysis of Matched Biopsy and Resection Material from Patients with Colon Cancer in the NCRI FOxTROT trial

R. Gray, B. Warren, P. Quirke, 2012 .

Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial

M. D. James, R. Butler, P. Quirke, 2015, Journal of Clinical Pathology.